An 18-month-old infant with congenital heart disease is diagnosed with acute bronchiolitis secondary to respiratory syncytial virus. Which therapy should be initiated?

An 18-month-old infant with congenital heart disease is diagnosed with acute bronchiolitis secondary to respiratory syncytial virus. Which therapy should be initiated?

• A. Albuterol
• B. Amoxicillin
• C. Azithromycin
• D. Ribavirin

Answer: (D)

Bronchiolitis from RSV in a child with congenital heart disease can become severe quickly, so treatment focuses on reducing viral burden and supporting the child while monitoring for complications. In high-risk infants, an antiviral option is used to help control RSV replication, and that is ribavirin. It’s given as inhaled therapy in a hospital setting and is reserved for severe disease or those with underlying cardiopulmonary conditions, where the potential benefit is greater. Other approaches aren’t the best fit here. Albuterol is a bronchodilator that may be tried in some wheezing illnesses, but it doesn’t have consistent evidence of benefit for routine bronchiolitis. Antibiotics like amoxicillin or azithromycin target bacteria, and bronchiolitis is viral; antibiotics aren’t indicated unless there is a suspected bacterial co-infection. Thus, the antiviral ribavirin is the therapy most appropriate for an infant with congenital heart disease facing severe RSV bronchiolitis.

Bronchiolitis from RSV in a child with congenital heart disease can become severe quickly, so treatment focuses on reducing viral burden and supporting the child while monitoring for complications. In high-risk infants, an antiviral option is used to help control RSV replication, and that is ribavirin. It’s given as inhaled therapy in a hospital setting and is reserved for severe disease or those with underlying cardiopulmonary conditions, where the potential benefit is greater.

Other approaches aren’t the best fit here. Albuterol is a bronchodilator that may be tried in some wheezing illnesses, but it doesn’t have consistent evidence of benefit for routine bronchiolitis. Antibiotics like amoxicillin or azithromycin target bacteria, and bronchiolitis is viral; antibiotics aren’t indicated unless there is a suspected bacterial co-infection. Thus, the antiviral ribavirin is the therapy most appropriate for an infant with congenital heart disease facing severe RSV bronchiolitis.